CN | EN
Current site :    CN   |   EN
Australia
Belgium
China
China Hong Kong SAR
Germany
Italy
Japan
Singapore
Spain
UAE
United Kingdom
United States
Global

Latest Publications

Publication

King & Wood Mallesons delighted to contribute to "China: Law & Practice" and "China:Trends and Developments" Chapters of Chambers "Banking & Finance 2023 " Global Practice Guide

King & Wood Mallesons is delighted to be a contributor of the "China: Law & Practice" and "China:Trends and Developments" Chapters of Chambers "Banking & Finance 2023" Global Practice Guide, published by Chambers and Partners recently.

23 November 2023

Publication

KWM 30th Anniversary Publication Series: Collection of KWM Intellectual Property Litigation Cases

Intellectual property stands as a pivotal driver of scientific and technological progress, safeguarding the rights and interests of innovators, fostering fair competition, and ensuring healthy economic development.

15 November 2023

Publication

King & Wood Mallesons delighted to contribute to China chapter of Chambers Joint Ventures 2023 Guide

Renowned legal rating agency Chambers and Partners recently released the global practice guide "Joint Ventures 2023," covering 15 jurisdictions. King & Wood Mallesons (KWM) was invited to contribute to the "China" chapter of this guide.

06 November 2023

LATEST THINKING
Publication
King & Wood Mallesons is delighted to be a contributor of the "China: Law & Practice" and "China:Trends and Developments" Chapters of Chambers "Banking & Finance 2023" Global Practice Guide, published by Chambers and Partners recently.

23 November 2023

Insight
The technical effect is a crucial factor in determination of inventiveness for pharmaceutical patents, and it relies heavily on experimental data. The presence and quality of experimental data can directly affect the grant or reject of a patent. Therefore, the acceptance of post-filing data has always been a matter of great concern.In accordance with the first-to-file principle under China's Patent Law, experimental data should be disclosed in the original patent application documents. However, due to factors such as the unpredictability of the prior art references cited by examiners and invalidation petitioners, the specific drafting of claims under the Markush system, and the diversity of experimental parameters, applicants often find it necessary to supplement experimental data after the application date to address challenges related to inventiveness and insufficient disclosure during prosecution and invalidation proceedings.Chapter 10, Section 3.5.1 of the latest “Guidelines for Patent Examination” amended in 2021 clearly outlines the examination principles for post-filing data, i.e. “Examiners should review experimental data submitted by applicants after the application date to satisfy the requirements of Article 22, Paragraph 3, and Article 26, Paragraph 3 of the Patent Law. The technical effect demonstrated by the post-filing data should be something that a person skilled in the art can derive from the content disclosed in the patent application.”Section 3.5.2 further specifies the standard for examination of “post-filing data for pharmaceutical patent applications” and provides examination examples related to pharmaceutical patent applications.The following will look at the degree of acceptance of post-filing data for pharmaceutical patents in practice from the aspect of CNIPA precedents. intellectual property-patents,healthcare and pharmaceuticals

16 November 2023

Publication
Intellectual property stands as a pivotal driver of scientific and technological progress, safeguarding the rights and interests of innovators, fostering fair competition, and ensuring healthy economic development.

15 November 2023

Explore our Topics

latest news

Firm Announcement

The Legal 500 releases its 2024 Asia Pacific rankings

On 15 November 2023, The Legal 500, a leading international legal directory, released its 2024 Asia Pacific rankings. King & Wood Mallesons (KWM) was recognized in 44 practice areas, with 28 Tier 1 practice area rankings. Of the 211 individuals on the list, 12 were named to the Hall of the Fame, 39 were ranked as Leading Individuals, 29 as Next Generation Partners, 15 as Rising Stars, and 138 were highly recommended lawyers in their respective practice areas.

17 November 2023

Firm Announcement

King & Wood Mallesons receives three awards for outstanding BRI legal services from Legal Daily

On 12 November 2023, King & Wood Mallesons (KWM) received three prestigious awards in recognition of the outstanding contributions to legal services related to the Belt and Road Initiative (BRI). The accolades were presented during the Fifth Belt and Road Initiative (BRI) Legal Service Typical Cases Conference, hosted by Legal Daily and organised by legaldaily.com in Beijing. The event brought together more than 200 guests from the Supreme People’s Court, the Ministry of Justice, the State-owned Assets Supervision and Administration Commission of the State Council, the China Law Society, the Belt and Road International Lawyers Association (BRILA), arbitration institutions, law schools, law firms and enterprises. Wu Wei and Wang Yue, partners of KWM, were present in the event and received the awards on behalf of the firm.

13 November 2023

Firm Announcement

KWM releases the second edition of Pharmaceuticals and the Law

The first edition of the Pharmaceuticals and the Law - A Guide to the Chinese Pharmaceuticals and Healthcare Market (Pharmaceuticals and the Law) was widely welcomed by readers since its launch in 2015. In recent years, the pharmaceuticals and healthcare industry in China has experienced significant transformations, driven by the full implementation of the Healthy China initiative and deep reforms to the pharmaceuticals and healthcare system. The foundational laws governing the industry have been revised, while new laws and regulations reflecting the changing times have been issued; various frameworks aligning with international standards have been put into practice; emerging businesses such as “online healthcare” are experiencing rapid growth. Additionally, China’s extensive anti-corruption campaign targeting the pharmaceutical and healthcare industry continues to intensify. Against this backdrop, the launch of the second edition of the Pharmaceuticals and the Law takes on greater significance.

26 October 2023

explore our media centre

explore our media centre

The latest news, deals and media releases from KWM.

EXPLORE

start your career with us

start your career with us

We seek to hire the best and are always looking for talented individuals.

VISIT CAREERS

KWM HENGQIN CROSS-JURISDICTIONAL PRACTICE OFFICE

KWM HENGQIN CROSS-JURISDICTIONAL PRACTICE OFFICE

We are strategically positioned in the world's growth markets and financial centres.

VISIT OFFICES